摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-{(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-[(1S)-1-methylpropyl]-2,5-dioxo-1-piperazinyl}-2-(2,6-dimethyl-3-pyridinyl)-N-(2hydroxyphenyl)acetamide | 872599-77-4

中文名称
——
中文别名
——
英文名称
2-{(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-[(1S)-1-methylpropyl]-2,5-dioxo-1-piperazinyl}-2-(2,6-dimethyl-3-pyridinyl)-N-(2hydroxyphenyl)acetamide
英文别名
2-{(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-[(1S)-1-methylpropyl]-2,5-dioxo-1-piperazinyl}-2-(2,6-dimethyl-3-pyridinyl)-N-(2-hydroxyphenyl)acetamide;2-[(2R,5R)-2-[(2S)-butan-2-yl]-5-(2,3-dihydro-1H-inden-2-yl)-3,6-dioxopiperazin-1-yl]-2-(2,6-dimethylpyridin-3-yl)-N-(2-hydroxyphenyl)acetamide
2-{(3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-6-[(1S)-1-methylpropyl]-2,5-dioxo-1-piperazinyl}-2-(2,6-dimethyl-3-pyridinyl)-N-(2hydroxyphenyl)acetamide化学式
CAS
872599-77-4
化学式
C32H36N4O4
mdl
——
分子量
540.662
InChiKey
ZHKUYNUPAFTGGZ-BFWDEDRPSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.9
  • 重原子数:
    40
  • 可旋转键数:
    7
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    112
  • 氢给体数:
    3
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] NOVEL COMPOUNDS<br/>[FR] PIPERAZINEDIONES UTILISES EN TANT QU'ANTAGONISTES DU RECEPTEUR DE L'OXYTOCINE
    申请人:GLAXO GROUP LTD
    公开号:WO2006000399A1
    公开(公告)日:2006-01-05
    Compounds of formula (I) wherein R1 is 2-indanyl, R2 is 1-methylpropyl, R3 is a group selected from 2, 6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R4 represents methyl and R5 represents hydrogen or methyl or, R4 and R5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.
    化合物的公式(I),其中R1是2-茚基,R2是1-甲基丙基,R3是从2,6-二甲基-3-吡啶基或4,6-二甲基-3-吡啶基中选择的基团,R4代表甲基,R5代表氢或甲基或者,R4和R5与它们连接的氮原子一起代表吗啡啉基团及其药用可接受的衍生物,描述了它们的制备过程,含有它们的药物组合物以及它们在医学中的用途,特别是作为催产素拮抗剂的用途。
  • Crystalline forms of (3R, 6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione
    申请人:Glaxo Group Limited
    公开号:US08815856B2
    公开(公告)日:2014-08-26
    Disclosed are crystalline forms of (3R,6R)-3-(2,3-dihydro-1H-inden-2-yl)-1-[(1R)-1-(2,6-dimethyl-3-pyridinyl)-2-(4-morpholinyl)-2-oxoethyl]-6-[(1S)-1-methylpropyl]-2,5-piperazinedione benzenesulfonate salt and pharmaceutical compositions thereof. Also disclosed are processes for the preparation the above compounds and methods for use thereof.
    本发明揭示了(3R,6R)-3-(2,3-二氢-1H-茚-2-基)-1-[(1R)-1-(2,6-二甲基-3-吡啶基)-2-(4-吗啉基)-2-氧代乙基]-6-[(1S)-1-甲基丙基]-2,5-哌嗪二酮苯磺酸盐的晶体形式及其制备方法和药物组合物。同时,本发明还揭示了上述化合物的使用方法。
  • Novel compounds
    申请人:Borthwick Alan David
    公开号:US20090247541A1
    公开(公告)日:2009-10-01
    Compounds of formula (I) wherein R 1 is 2-indanyl, R 2 is 1-methylpropyl, R 3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R 4 represents methyl and R 5 represents hydrogen or methyl or, R 4 and R 5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.
    化合物的公式(I),其中R1为2-吲哚基,R2为1-甲基丙基,R3为从2,6-二甲基-3-吡啶基或4,6-二甲基-3-吡啶基中选择的基团,R4代表甲基,R5代表氢或甲基或R4和R5与它们连接的氮原子一起代表吗啡啡诺,以及其制备过程,含有它们的制药组合物和它们在医学上的用途,特别是它们作为催产素拮抗剂的用途。
  • Piperazinediones as Oxytocin Receptor Antagonists
    申请人:Borthwick David Alan
    公开号:US20070254888A1
    公开(公告)日:2007-11-01
    Compounds of formula (I) wherein R 1 is 2-indanyl, R 2 is 1-methylpropyl, R 3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R 4 represents methyl and R 5 represents hydrogen or methyl or, R 4 and R 5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.
    化学式为(I)的化合物,其中R1为2-茚芳基,R2为1-甲基丙基,R3为从2,6-二甲基-3-吡啶基或4,6-二甲基-3-吡啶基中选择的基团,R4代表甲基,R5代表氢或甲基,或者R4和R5与它们所连接的氮原子一起代表吗啡啶基团,以及它们的药学上可接受的衍生物的制备方法、含有它们的制剂和它们在医学上的应用,特别是它们作为催产素拮抗剂的应用。
  • NOVEL COMPOUNDS
    申请人:Borthwick Alan David
    公开号:US20110152262A1
    公开(公告)日:2011-06-23
    Compounds of formula (I) wherein R 1 is 2-indanyl, R 2 is 1-methylpropyl, R 3 is a group selected from 2,6-dimethyl-3-pyridyl or 4,6-dimethyl-3-pyridyl, R 4 represents methyl and R 5 represents hydrogen or methyl or, R 4 and R 5 together with the nitrogen atom to which they are attached represent morpholino and pharmaceutically acceptable derivatives thereof are described, as are processes for their preparation, pharmaceutical compositions containing them and their use in medicine, particularly their use as oxytocin antagonists.
    化学式为(I)的化合物,其中R1为2-吲哚基,R2为1-甲基丙基,R3为从2,6-二甲基-3-吡啶基或4,6-二甲基-3-吡啶基中选择的基团,R4代表甲基,R5代表氢或甲基,或R4和R5与它们所连接的氮原子一起代表吗啡啶基,以及其制备方法、含有它们的制药组合物和在医药上的应用,特别是它们作为催产素拮抗剂的应用。
查看更多